WHAT THE HUMAN DATA SAY
Evidence before enthusiasm.
Small human trials show that NR or NMN can raise NAD-related biomarkers and may affect selected metabolic endpoints. Trials have not established longer life, broad rejuvenation or reliable improvement across muscle, cognition and energy.
This grade reflects clinically meaningful human evidence for the use described here. It is not a score for popularity, mechanism, animal lifespan results or the number of products already being sold.
HOW IT FITS
A practical role—without pretending it is universal.
Treat this as an optional, time-limited experiment only after sleep, training, diet and metabolic risk are addressed. Prefer a legally marketed, independently tested oral product over intravenous wellness claims.
TRACK WHAT MATTERS
Know whether it is creating value.
The specific outcome being tested
Product identity and current regulatory status
Glucose, liver or other labs only when clinically relevant
SAFETY & BOUNDARIES
What should make you pause.
- Long-term outcome data are limited.
- U.S. regulatory treatment of NMN has changed and should be checked before sale or recommendation.
- FDA has warned that food-grade NAD+ ingredients are not suitable for sterile compounding.
BOOK CONNECTIONS
Where this idea enters the longevity conversation.
Book inclusion explains why the idea is culturally important; the evidence grade above determines how strongly The Modern Bio treats the claim.